Last update 21 Nov 2024
HY-004 (Juventas)
Last update 21 Nov 2024
Overview
Basic Info
Drug Type Autologous CAR-T |
Synonyms Anti-CD19/CD20 CAR-T cell therapy (Juventas Cell Therapy), CD19/CD20 CART cell therapy (Juventas Cell Therapy), CD19/CD20 chimeric antigen receptor Tcell therapy (Juventas Cell Therapy) + [2] |
Target |
Mechanism CD19 inhibitors(B-lymphocyte antigen CD19 inhibitors), CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), Gene transference + [1] |
Therapeutic Areas |
Inactive Indication- |
Originator Organization  Juventas Cell Therapy Ltd.Startup |
Active Organization Juventas Cell Therapy Ltd.Startup |
Inactive Organization- |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
7
Clinical Trials associated with HY-004 (Juventas)A Multi-center, Open Label, Single-arm, Phase I/II Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
A Phase I/II, Single Arm, Multi-center Study Evaluating the Safety and Efficacy of HY004 in Adult Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (r/r B-ALL)
A Clinical Study to Evaluate the Safety and Effectiveness of CD19- BCMA CAR - T Cells Immunotherapy in Patients With Relapsed or Refractory Acute B Lymphocytic Leukemia
100 Clinical Results associated with HY-004 (Juventas)
Login to view more data
100 Translational Medicine associated with HY-004 (Juventas)
Login to view more data
100 Patents (Medical) associated with HY-004 (Juventas)
Login to view more data
1
Literatures (Medical) associated with HY-004 (Juventas)BloodQ1 · MEDICINE
Optimized tandem CD19/CD20 CAR-engineered T cells in refractory/relapsed B cell lymphoma
Q1 · MEDICINE
Article
Author: Liu, Yang ; Liu, Wanli ; Tong, Chuan ; Wang, Chunmeng ; Zhang, Wenying ; Ti, Dongdong ; Dai, Hanren ; Ji, Xingyu ; Wang, Yao ; Han, Weidong ; Han, Xiao ; Wu, Zhiqiang ; Guo, Yelei ; Yang, Qingming ; Zhang, Yajing
100 Deals associated with HY-004 (Juventas)
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| B-Cell Lymphoma | Phase 2 | - | Juventas Cell Therapy Ltd.Startup | 31 Aug 2024 |
| Pre B-cell acute lymphoblastic leukemia | Phase 2 | - | Juventas Cell Therapy Ltd.Startup | 31 Aug 2024 |
| CD19-positive B-cell acute lymphoblastic leukemia | Phase 1 | CN | Juventas Cell Therapy Ltd.Startup | 26 Sep 2023 |
| CD22 Positive B-cell Acute Lymphoblastic Leukemia | Phase 1 | CN | Juventas Cell Therapy Ltd.Startup | 26 Sep 2023 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free